Next Phase Newsletter

A Life Science focused investment fund based in Shanghai, China was founded by successful Chinese and American entrepreneurs in the healthcare industry. The fund primarily considers investments based in China or has a significant China nexus. For example, the company must have a principal market in China, or R&D/manufacturing/sales in China. The fund prefers to follow and take minority stake. Investment size varies but typically ranges from US$1-4 million. The fund prefers business models that are marketing/sales oriented (vs. technology oriented). The fund is actively seeking new investment opportunities.

Currently the fund is looking for innovative antibiotics or alternatives to antibiotics in human health, animal health, and agriculture. For the stage of development, the fund seeks products that are able to enter the market within 2 years post investment. Historically, the fund invested in a medical supplier, medical devices, and AgBio.

The fund seeks an experienced management team that has “done it before.” The fund will consider US-based companies as long as the China nexus criteria is met. The firm seeks to make minority investment and typically requires China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate VC based in Shanghai, China with a recently established U.S. branch in California manages a $100M fund and typically invests $500K-$1M per company with the ability for acquisition at up to $100M. The fund is particularly seeking U.S.-based companies with innovative technologies to bring to the China market, and supports FDA-approved companies to gain CFDA approval.

The firm is seeking truly innovative medical devices and diagnostics in women’s health (OBGYN), neonatal healthcare, geriatric pregnancy, and other women’s health indications; women and children health-related products or services; life science-related products to be used in the research field; diagnostic kits; and immunotherapy and cell therapy services. The firm is not interested in pharmaceuticals or biotech therapeutics due to the longer development timeline, and particularly seeks late-stage technologies that are near or on-the-market generating revenue. The firm is open to all classes of devices.

The firm is seeking to invest or acquire private companies. Companies with products to be introduced to China is preferred.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A China-based investment firm has raised 2 funds to date and has recently closed its second fund in 2015. The firm invests at various stages—typically investing in Series A rounds or later. The firm is able to invest anywhere from USD 500K or more per company, and is flexible with the investment size depending on the deal. The firm has no set number of allocations it plans to make, but could invest in as many as 5-10 companies in the next 12 months. The firm both leads and coinvests. The firm invests globally, and is actively looking for new investment opportunities.

The firm invests in innovative medical technologies and digital health. In medtech, the firm is generally opportunistic in terms of the class of device and therapeutic areas. However, the firm is more interested in devices for cardiovascular and aging related diseases such as hypertension, Alzheimer’s, diabetes, etc; cosmetic devices; and sports medicine/rehabilitation. The device needs to target a high unmet medical need in China. The firm is interested in clinical to on-the-market products. The firm looks for POC therapeutics and devices, preferably with regulatory approval.

The firm may obtain a BOD seat depending on the opportunity. The firm is looking for companies with an exit strategy within 5 years post investment. The firm has the knowledge and know-how to help portfolio companies bring their respective products into the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A South Korea-based pharmaceutical company is interested in forming strategic partnerships with biopharmaceutical companies that are interested in entering the Korean market. The structure of the partnership includes in-licensing, co-marketing, co-promotion, join-ventures, and equity investment. The company is actively seeking new partnership opportunities.

The firm is currently seeking products in the following therapeutic areas: Cardiovascular disorder such as hypertension; Endocrinology disorder such as Type I, II Diabetes & Diabetic complications; CNS disorder such as Depression, Schizophrenia, Anxiety disorder, Insomnia, Alzheimer’s disease, Parkinson’s disease and Various pain types; Ophthalmic disorder; Respiratory disorder; Oncology disorder; Degenerative/Age-related diseases. The company prefers to invest in products that have attained human proof of concept, and is also interested in partnering with companies that have products on the market.

The firm will partner with companies from around the world that are interested in entering the Korean market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A children’s health foundation has launched a new financial vehicle to make program related investment in commercial companies developing technologies that can improve children’s health. The foundation expects to make 2-3 equity allocations in the current year. Typical investments range from $150,000 – $250,000 in pre-Series A rounds.  The foundation is seeking opportunities globally.

The foundation funds early stage projects to help them reach scale and sustainability. The foundation is looking for high impact innovations in children’s health with a special interest in neonatal care and pediatric neurology. The foundation is agnostic to technology sectors. The foundation is interested in single assets as well as platform technology that can be applied to the pediatric field.

The foundation seeks privately held companies with competent management teams with sector expertise. The foundation typically seeks board representation post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices throughout the US focuses on several verticals including medical devices, and diagnostics. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm’s target investment size is $1-3M for each portfolio company spread over 1-3 rounds. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in early stage research tools, diagnostics, and medical devices. The firm is generally opportunistic in terms of subsectors and indications. The firm will consider products as early as in proof of concept stage, but typically looks at technology 12-18 months from attaining revenue. The company must have solid patent protection.

The firm seeks a strong and experienced management team that has a track record of bringing concept to market, and may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital firm based in California held a first close of a new fund in late 2015 of $75M, and expects to be fully closed in 2016 at $150M. The fund’s investment strategy is somewhat flexible, but seeks to initially invest in series A rounds in the range of $2M-$3M then provide capital throughout the company’s life via additional investments. The firm may write smaller checks (in the range of $250K) to companies that are of very high interest to the fund, but are deemed as too early, to serve as a placeholder for subsequent financing rounds. In terms of capital structure, the firm prefers to participate in priced equity rounds, however convertible notes or other structures may be considered in certain cases. The firm will act as a lead or follow-on investor depending on the nature/terms of the deal and other investors participating in the round.

The firm is most interested in disruptive technologies that target extreme inefficiencies in the healthcare system, such as digital health solutions based on artificial intelligence or big data platforms, as well as cutting-edge technologies and applications in the field of synthetic biology, or other technologies taking elements of data science to improve molecular processes. The firm is not interested in traditional medical devices and diagnostics, but rather devices whose core IP lies within in the backend or software component of the technology.

The firm is open to companies globally, but prefers to invest in companies based on the West Coast. Typically, companies that aren’t located in the U.S. would need to have some operations based in the United States. A lot of emphasis is placed on the strength of the management team when making an investment decision, and the firm seeks to work with entrepreneurs who have a strong understanding of their market and sound logic behind why their vision and business model will be successful. Although successful, repeat entrepreneurs are highly valued, the firm will work with entrepreneurs of all experience levels. Board seats are not required along with an investment, but may be sought depending on the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com